Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Citius Pharmaceuticals (NASDAQ:CTXR) to a hold rating in a report issued on Tuesday,Zacks.com reports.

CTXR has been the subject of a number of other research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Citius Pharmaceuticals in a research note on Wednesday, March 11th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Stock Performance

Citius Pharmaceuticals stock opened at $0.58 on Tuesday. The company has a 50 day moving average price of $0.77 and a 200 day moving average price of $0.89. Citius Pharmaceuticals has a 52 week low of $0.48 and a 52 week high of $2.48. The firm has a market capitalization of $15.92 million, a price-to-earnings ratio of -0.27 and a beta of 1.05.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). The company had revenue of $1.67 million for the quarter, compared to analysts’ expectations of $10.23 million. Equities analysts forecast that Citius Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of institutional investors have recently modified their holdings of CTXR. XTX Topco Ltd acquired a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at $32,000. NewEdge Advisors LLC acquired a new stake in shares of Citius Pharmaceuticals during the 2nd quarter valued at $40,000. Asset Advisory Group Inc. acquired a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at $46,000. Finally, Heights Capital Management Inc. acquired a new stake in shares of Citius Pharmaceuticals during the 4th quarter valued at $622,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Key Citius Pharmaceuticals News

Here are the key news stories impacting Citius Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Citius Pharmaceuticals and maintained a $4.00 price target, signaling meaningful upside potential from current levels. Citius Pharmaceuticals’ (CTXR) “Buy” Rating Reaffirmed at HC Wainwright
• Neutral Sentiment: The firm also issued updated earnings estimates for FY2026 and FY2027, with expectations for ongoing losses, including FY2026 EPS of ($1.87) and FY2027 EPS of ($0.81). While these forecasts show improvement over time, they still reflect a pre-profit company. HC Wainwright earnings estimate updates for Citius Pharmaceuticals
• Neutral Sentiment: HC Wainwright’s quarterly projections for Citius Pharmaceuticals remain negative across the forecast period, including Q3 2026 EPS of ($0.36), Q4 2026 EPS of ($0.25), Q1 2027 EPS of ($0.28), Q2 2027 EPS of ($0.20), Q3 2027 EPS of ($0.19), and Q4 2027 EPS of ($0.16). HC Wainwright quarterly earnings estimates for Citius Pharmaceuticals

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.